• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LUAN Baolei, XU Xinjun, LIANG Guiting, YOU Mengmeng, LIU Guozhu. Determination of related genotoxic impurities in olmesartan medoxomil by HPLC-MS[J]. Journal of China Pharmaceutical University, 2019, 50(3): 325-329. DOI: 10.11665/j.issn.1000-5048.20190308
Citation: LUAN Baolei, XU Xinjun, LIANG Guiting, YOU Mengmeng, LIU Guozhu. Determination of related genotoxic impurities in olmesartan medoxomil by HPLC-MS[J]. Journal of China Pharmaceutical University, 2019, 50(3): 325-329. DOI: 10.11665/j.issn.1000-5048.20190308
shu

Determination of related genotoxic impurities in olmesartan medoxomil by HPLC-MS

More Information
    Graphical Abstract
    • Abstract
  • The aim of this study was to establish a high performance liquid chromatography-mass spectrometry method for the determination of 5-(4′-(bromomethyl)-［1, 1′-biphenyl］-2-yl)- 1H-tetrazole(BBT1)and 5-(4′-(dibromomethyl)-［1, 1′-biphenyl］-2-yl)-1H-tetrazole(BBT2), which are two genotoxic impurities in olmesartan medoxomil. Chromatographic separation was based on an Agilent Zorbax Eclipse Plus C18(250 mm × 4. 6 mm, 5 μm)column using water(containing 0. 1% formic acid)- acetonitrile as mobile phase in gradient elution mode. Mass spectrometry was operated in positive ion mode. Selective ion monitors were set at m/z 315 for BBT1 and at m/z 395 for BBT2. Good linear correlations were observed in the range of 0. 009 4- 0. 561 0 μg/mL(r=0. 998)with the quantification limit at 9. 35 ng/mL and the detection limit at 3. 12 ng/mL for BBT1, and in the range of 0. 018 2- 0. 547 5 μg/mL(r=0. 999)with the quantification limit at 18. 25 ng/mL and the detection limit at 6. 08 ng/mL for BBT2. Furthermore, the average recoveries of the three spiked concentration level were 96. 5%(n=9, RSD=4. 8%)and 98. 0%(n=9, RSD=5. 1%)for BBT1 and BBT2, respectively. The proposed method is simple, specific and accurate, and quite suitable for the determination of BBT1 and BBT2 in olmesartan medoxomil.
    • FullText(HTML)
    • References (15)
  • [1]
    EMA(European Medicines Agency).Guidelines on the Limits of Genotoxic Impurities[S/OL].(2006-06-28)[2019-01] .http://www.EMA.europa.eu/docs/en_GB/document_ library / Scientific_ guideline/2009/09/WC500002903.pdf.
    [2]
    CHMP Safety Working Party.Question & answers on the CHMP Guideline on Limits of Genotoxic Impurities[S/OL].(2009-12)[2019-01] .http://www.EMA.europa.eu/docs/en_ GB/document_ library/ Scientific_ guideline/2009/09/WC500002907.pdf.
    [3]
    Food and Drug Administration.Guidance for Industry:Genotoxic and Carcinogenic Impurities in Drug Substances and Products:Recommended Approaches(Draft Guideline)[S].USA:U.S.Department of Health and Human Services,Food and Drug Administration,Center for Drug Evaluation and Research(CDER),2008.
    [4]
    The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.ICH Harmonised Trepartite Guideline:Assessment and Control of DNA Reactive(Mutagenic)Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7(R1)[S/OL].(2017-05)[2019-01] .https://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M7/M7_R1_Addendum_Step_4_2017_0331.pdf.
    [5]
    Argentine MD,Owens PK,Olsen BA.Strategies for the investigation and control of process-related impurities in drug substances[J].Adv Drug Deliv Rev,2007,59(1):12-28.
    [6]
    Song DM,Xu QY,Ren MT,et al.HPLC-QTOF MS determination of ethyl p-toluenesulfonate in enalapril maleate and its intermediate[J].Chin J Pharm Anal(药物分析杂志),2012,32(5):834-837.
    [7]
    Raman NV,Prasad AV,Ratnakar RK.Strategies for the identification,control and determination of genotoxic impurities in drug substances:a pharmaceutical industry perspective[J].J Pharm Biomed Anal,2011,55(4):662-667.
    [8]
    Antonio G,Werner K,Hans UG.Overall impact of the regulatory requirements for genotoxic impurities on the drug development process[J].J Pharm Sci,2011,43(1/2):1-15.
    [9]
    Fan ZP.Pharmacological and Toxicological Research Progress on Olmesartan Medoxomil[J].Food Drug(食品与药品),2014,16(5):376-378.
    [10]
    Feng YF,Lei J,Lv JL,et al.A new angiotensin n receptor blocker,olmesartan medoxomil[J].Chin New Drugs J(中国新药杂志),2003,12(7):520-523.
    [11]
    Koike H,Sada T,Mizuno M.In vitro and in vivo pharmacology of olmesartan medoxomil,an angiotensin II type AT1 receptor antagonist[J].J Hypertens Suppl,2001,19(1):s3-14.
    [12]
    Zhu JB,Qiu XM,Guo SW,et al.To establish an HPLC Method for determination of olmesartan medoxomil and its related substances[J].J Hunan Normal Univ(湖南师范大学学报),2013,10(2):81-84.
    [13]
    Yuan QY.Analytical Separation of genotoxic impurities and new quality standard for olmesartan medoxomil prodution[D].Zhejiang:Zhejiang University of Technology,2017.
    [14]
    Pan HJ,Wu TZ,Zhang FL,et al.HPLC determination of olmesartan medoxomil and its related substances[J].Chin J Pharm Anal(药物分析杂志),2008,28(11):1883-1886.
    [15]
    Yuan QY,Chen C,Li JC,et al.Determination of genotoxic impurity in olmesartan medoxomil by HPLC[J].Chin J Mod Appl Pharm(中国现代应用药学),2017,34(3):407-409.
    • Related Articles

  • Related Articles

    [1]WU Lingxi, DU Yixuan, GAO Xiangdong. Inhibitory effect of IL-27 on the overactivation of microglia[J]. Journal of China Pharmaceutical University, 2024, 55(6): 801-808. DOI: 10.11665/j.issn.1000-5048.2024022702
    [2]WANG Sibu, CHEN Ying, DING Yang, XIAO Ting, LIU Wen, SHEN Xiangchun, TAO Ling, LUO Xinghong. Preparation of paeonol nanoemulsion and investigation of vascular endothelial cells uptake[J]. Journal of China Pharmaceutical University, 2022, 53(6): 690-697. DOI: 10.11665/j.issn.1000-5048.20220607
    [3]ZHANG Wendian, CUI Jie, XIA Yifan, ZHANG Xin, DUAN Shaofeng. Synthesis of two folate conjugates and their targeting effect in vitro[J]. Journal of China Pharmaceutical University, 2021, 52(4): 447-454. DOI: 10.11665/j.issn.1000-5048.20210407
    [4]WANG Xiaoying, WANG Xiaying, QIU Liangzhen, OUYANG Huizhi, XU Wei. Cytotoxicity and cellular uptake of paclitaxel-loaded carboxymethyl chitosan-rhein polymeric micelles in MCF-7 cells[J]. Journal of China Pharmaceutical University, 2020, 51(1): 33-37. DOI: 10.11665/j.issn.1000-5048.20200106
    [5]XU Wanyi, QIAO Jianbin, MA Bo, WANG Ran, QIAN Wen, LU Weidong. Cellular immunity of influenza vaccine lyophilized liposome produced by freeze-thawing[J]. Journal of China Pharmaceutical University, 2015, 46(6): 730-733. DOI: 10.11665/j.issn.1000-5048.20150616
    [6]CHEN Zhipeng, ZHANG Liujie, HE Jiayu, FENG Changhua, ZHAO Xiaoyi, ZHAO Can, CHENG Tiefeng. Cellular uptake of Brucine-loaded chitosan nanoparticles on human hepatic cancer cells in vitro[J]. Journal of China Pharmaceutical University, 2014, 45(6): 674-680. DOI: 10.11665/j.issn.1000-5048.20140610
    [7]LI Wenting, WANG Lu, ZHANG Can. Influence of surface characteristics on hepatocellular carcinoma cells uptake of nano-liposomes[J]. Journal of China Pharmaceutical University, 2013, 44(3): 244-248. DOI: 10.11665/j.issn.1000-5048.20130311
    [8]Bifendate liposomes modified by bile and its role in enhancing hepatocytes uptake in vitro[J]. Journal of China Pharmaceutical University, 2010, 41(4): 342-347.
    [9]SHAO Jing-ping, ZHANG Shan-fei, CHEN Yuan-cheng, YANG Wen-liang, LIU Xiao-quan. Cellular uptake characteristics of salvianolic acid B in myocardial cells and blood vessel endothelial cells[J]. Journal of China Pharmaceutical University, 2009, 40(3): 263-268.
    [10]Preparation of Brush Border Membrane Vesicles and Preliminary Studies on the Uptake of 5-FU[J]. Journal of China Pharmaceutical University, 2001, (6): 23-25.

  • Cited by

    Periodical cited type(6)

    1. 万瑞融，王希斌. CTLA-4纳米抗体与肿瘤适配体共修饰的双靶向脂质体构建. 医学理论与实践. 2024(01): 5-7+38 .
    2. 李建安，陈慧华，杨兰平，文玲波，贾燕华. 靶向药物和通路抑制剂治疗复发难治性B细胞非霍奇金淋巴瘤的研究进展. 广西医学. 2022(14): 1653-1656 .
    3. 陈敏，方翼. 双特异性抗体的免疫原性. 中国临床药理学与治疗学. 2021(10): 1208-1212 .
    4. 刘婧琳，吴春暖，宋晓坤. 抗肿瘤药物临床超常用药分析. 中国药房. 2020(07): 873-878 .
    5. 赵秋玲，杨琳，谢瑞祥. 9种获批上市的抗PD-1/PD-L1单抗药物的特征综述. 中国药房. 2020(18): 2294-2299 .
    6. 辛中帅，张彦彦，晋小雁，杨建红. 我国已上市治疗用单抗类产品分析. 中国药事. 2019(09): 986-990 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (731) PDF downloads (967) Cited by(8)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：292652

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return